487 filings
Page 3 of 25
6-K
xi6acv9hmc68 mlzp6gu
15 Jun 23
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome
4:30pm
EFFECT
jhb7wnrirphp66 xqcg6
12 Jun 23
Notice of effectiveness
12:15am
EFFECT
mg1z6301dksh
12 Jun 23
Notice of effectiveness
12:15am
424B3
0482up3v27ql9
9 Jun 23
Prospectus supplement
4:36pm
424B3
1x0e60f
9 Jun 23
Prospectus supplement
4:35pm
CORRESP
01gtc7tu
9 Jun 23
Correspondence with SEC
12:00am
CORRESP
i27st5
9 Jun 23
Correspondence with SEC
12:00am
UPLOAD
j381bp2q09h1by90b05x
8 Jun 23
Letter from SEC
12:00am
UPLOAD
n6vw0
8 Jun 23
Letter from SEC
12:00am
F-3
49bw1z
1 Jun 23
Shelf registration (foreign)
4:35pm
F-1
a0ygv1b
1 Jun 23
Registration statement (foreign)
4:31pm
6-K
8v1o 5ii8d
30 May 23
Notice of the Annual General Meeting of Shareholders
8:00am
6-K
ih0vpbg6s826855aczih
26 May 23
Report of Foreign Private Issuer
5:29pm
6-K
hhmu8bfb8
16 May 23
Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results
4:30pm
6-K
l1wfyhw av3j
2 May 23
Convertible Loan Agreement
8:30am
NT 20-F
ib18u4f5
1 May 23
Notice of late annual filing (foreign)
4:59pm
SC 13D/A
50po4lbpom
27 Apr 23
Altamira Therapeutics / Meyer Thomas ownership change
4:30pm
6-K
qcsndos
18 Apr 23
Report of Foreign Private Issuer
8:00am
CERT
gdoj77lk
17 Apr 23
Certification of approval for exchange listing
12:21pm